Biogen: Analyst Estimates & Ratings

Biogen Inc. (BIIB) is a leading biopharmaceutical company that has underperformed the broader market over the past year, declining 32.4%. Despite this, the company's Q2 2025 earnings exceeded expectations, driven by strong growth in new product launches and rare disease therapies. Analysts expect BIIB's EPS to decline 3.6% in the current fiscal year, and the consensus rating is a "Moderate Buy" based on 13 "Strong Buy" ratings and 20 "Holds."

Biogen Inc. (BIIB) reported its Q2 2025 earnings, posting adjusted EPS of $5.47 and revenue of $2.6 billion, both well above expectations. The company's stock has significantly underperformed the broader market over the past year, declining 32.4% compared to the S&P 500 Index's 14.3% rise. Despite this, the company's earnings were driven by strong growth in new product launches and rare disease therapies, signaling confidence in sustained growth.

Biogen's earnings were driven by the rapid uptake of new product launches and solid growth in rare disease therapies like Skyclarys. The company's Leqembi sales also hit $63 million in the U.S., contributing to the overall positive results. Although older multiple sclerosis drugs continued to decline, the momentum in newer treatments helped lift overall results.

Analysts expect Biogen's EPS to decline 3.6% in the current fiscal year, ending in December. The consensus rating is a "Moderate Buy" based on 13 "Strong Buy" ratings and 20 "Holds." This configuration is less bullish than two months ago, when 14 analysts suggested a "Strong Buy."

References:
[1] https://www.marketbeat.com/instant-alerts/filing-stoneridge-investment-partners-llc-has-2-million-stake-in-biogen-inc-biib-2025-08-20/
[2] https://finance.yahoo.com/news/biogen-stock-analyst-estimates-ratings-090559818.html